
Objectives Megakaryocytic dysplasia (MegDys) is a common morphologic abnormality in myelodysplastic syndromes (MDS), but its clinical and molecular significance remains incompletely understood. We characterized hematologic, cytogenetic, and mutational features associated with MegDys and identified independent associations after risk adjustment.Methods A total of 169 patients with MDS (2022 WHO classification) were retrospectively classified into MegDys-positive (n = 89) and MegDys-negative (n = 80) groups based on bone marrow morphology. Clinical, hematologic, cytogenetic, and targeted sequencing data were compared between groups, with the false discovery rate (FDR) controlled by the Benjamini–Hochberg method. Multivariable Firth logistic regression was performed, adjusting for blast percentage, complex karyotype, MDS subtype, age, sex, and mutation status.Results MegDys+ patients exhibited lower peripheral blood counts, higher bone marrow blast percentages, and enrichment of RUNX1, EZH2, and CBL mutations, whereas SF3B1 mutations were more frequent in MegDys − patients (all FDR-corrected P < 0.05). In multivariable analysis, EZH2 mutation was the only factor independently associated with MegDys (adjusted OR = 3.38, 95% CI: 1.12–12.03, P = 0.030); RUNX1 and CBL showed suggestive but non-significant associations (aOR: 2.69 and 3.15), indicating that their enrichment was largely attributable to the higher-risk disease context.Discussion MegDys is not merely a morphological correlate of high-risk MDS: EZH2 retained an independent association after risk adjustment, whereas the signals for RUNX1 and CBL were largely explained by confounding.Validation in larger cohorts is warranted.Conclusions MegDys is characterized by severe thrombopoietic abnormalities, high-risk disease features, and distinct mutation enrichment patterns. After risk adjustment, EZH2 mutation emerged as the sole independent molecular correlate of MegDys.
Objectives To explore the unmet communication, information, and support needs of people living with multiple myeloma (MM) and identify helpful and unhelpful phrases or behaviors used by family and friends (F&F) and healthcare professionals (HCPs) in the Patient Understanding of Multiple Myeloma and Communication Experiences (PUMMaCE) study.Methods An online survey was co-developed with HCPs and people living with MM, as part of the study. The survey consisted of closed- and open-ended questions. A framework analysis was conducted on the qualitative free-text responses to identify key themes related to patients’ communication experiences and preferences.Results In total, 138 people living with MM completed the survey. The free-text comments were organized into six overarching themes. Making sense of MM, gaps in understanding MM, communicating MM to F&F, F&F behaviors, HCP interactions, and healthcare systems and pathways. Many felt confused by the complex terminology and had unanswered questions about their disease, treatment, and prognosis. Limited understanding often led to F&F exhibiting unhelpful behaviors. Yet, there were also examples of positive communication and behaviors that supported respondents in managing their day-to-day life.Discussion and conclusion Significant gaps in communication, information, and support exist in MM care. The findings of this survey illustrate the challenges posed by the complexity of the language used routinely by HCPs, which can lead to distress and misunderstandings. These data will be used to inform the production of educational materials to improve communication among patients, their families, and HCPs.
Background Primary pure red cell aplasia (PRCA) is a rare hematologic disorder characterized by severe anemia and selective erythroid hypoplasia in the bone marrow. While immune-mediated mechanisms are central to its pathogenesis, the role of soluble inflammatory factors in the bone marrow microenvironment remains poorly understood.Methods Bone marrow plasma and lineage-negative (Lin-) hematopoietic progenitor cells were obtained from untreated PRCA patients and healthy controls. K562 erythroleukemia cells were co-cultured with plasma and induced to undergo erythroid differentiation using hemin. Hemoglobin production was assessed by benzidine staining, and GATA1/GATA2 protein expression was analyzed by Western blotting. Erythroid colony-forming assays were performed to quantify small and large burst-forming unit-erythroid (BFU-E) and colony-forming unit-erythroid (CFU-E) colonies. Cytokine levels in bone marrow supernatant were measured. The effects of dexamethasone, cyclosporine A, and rapamycin on colony formation were also evaluated.Results PRCA bone marrow plasma significantly inhibited hemoglobinization in K562 cells and suppressed GATA2 expression without affecting GATA1. Lin- cells from PRCA patients formed markedly fewer large BFU-E colonies than those from controls. Treatment with dexamethasone alone or in combination with cyclosporine A or rapamycin significantly restored large BFU-E colony formation. Cytokine analysis revealed significantly elevated levels of IL-6 and IL-10, with a trend toward increased IL-17A, in PRCA bone marrow plasma.Conclusions Soluble factors in the PRCA bone marrow microenvironment may contribute to impaired erythroid progenitor function and hemoglobinization.
Introduction Monoclonal Gammopathy of Clinical Significance (MGCS) challenges the traditional binary classification of plasma cell disorders as either benign or malignant. MGCS is defined by a small B-cell or plasma cell clone that does not meet criteria for malignancy yet secretes a pathogenic paraprotein causing significant end-organ damage.Objectives This review aims to decode the mechanisms of paraprotein-mediated organ injury, chart the diverse clinical spectrum of MGCS, integrate modern diagnostic approaches, and propose a precision medicine roadmap for targeted therapeutic intervention.Methods We performed a structured narrative review. PubMed/MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Library were searched from inception to 30 September 2026 using terms for MGCS, MGUS, MGRS, MGNS, AL amyloidosis, paraprotein, and clone-directed therapy. Two reviewers independently screened titles/abstracts and full texts; peer-reviewed original studies, guidelines, consensus reports, and selected case series/reports were included. Data on pathophysiology, clinical phenotype, diagnosis, treatment, and outcomes were extracted. Study quality was appraised using design-specific domains (risk of bias, sample size, diagnostic ascertainment, confounding, follow-up, statistical reporting, and directness); because of heterogeneity, no meta-analysis was performed, and evidence was synthesized narratively with qualitative certainty ratings.Results The pathogenic mechanisms extend beyond simple deposition to include autoantibody mimicry and direct cellular toxicity. MGCS manifests as a master of disguise, with organ involvement including cardiac amyloidosis, renal dysfunction (MGRS), peripheral neuropathies (MGNS), and dermatologic conditions. Diagnostic advances incorporating mass spectrometry and serum free light chain assays have enhanced sensitivity over traditional electrophoresis. Management requires a paradigm shift from empiric immunosuppression to clone-directed therapies, including anti-CD20 agents, proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and emerging BCMA-targeting therapies, tailored to immunoglobulin isotype, pathogenic mechanism, and patient frailty.Discussion Persistent challenges include the absence of early biomarkers, lack of validated MGCS-specific response criteria, and the need for therapies targeting both the clone and toxic paraprotein directly. Multidisciplinary collaboration and integration of multi-omics with artificial intelligence hold promise for improved risk stratification.Conclusion Conquering MGCS requires increased recognition, early diagnosis, and targeted intervention to prevent irreversible organ injury and improve patient outcomes.